Abstract
<div>Abstract<p>The <i>PPARG</i> gene encoding the nuclear receptor PPARγ is activated in bladder cancer, either directly by gene amplification or mutation, or indirectly by mutation of the <i>RXRA</i> gene, which encodes the heterodimeric partner of PPARγ. Here, we show that activating alterations of <i>PPARG</i> or <i>RXRA</i> lead to a specific gene expression signature in bladder cancers. Reducing PPARG activity, whether by pharmacologic inhibition or genetic ablation, inhibited proliferation of PPARG-activated bladder cancer cells. Our results offer a preclinical proof of concept for PPARG as a candidate therapeutic target in bladder cancer. <i>Cancer Res; 77(24); 6987–98. ©2017 AACR</i>.</p></div>
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call